231 related articles for article (PubMed ID: 18007550)
21. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
Arroyo V; Jiménez W
J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
[TBL] [Abstract][Full Text] [Related]
22. [Hyponatremia in liver cirrhosis: pathogenesis and treatment].
Guevara M; Ginès P
Endocrinol Nutr; 2010 May; 57 Suppl 2():15-21. PubMed ID: 21130958
[TBL] [Abstract][Full Text] [Related]
23. Hyponatremia in cirrhosis: clinical features and management.
Martín-Llahí M; Guevara M; Ginès P
Gastroenterol Clin Biol; 2006 Oct; 30(10):1144-51. PubMed ID: 17075468
[TBL] [Abstract][Full Text] [Related]
24. Hyponatremia in Cirrhosis: An Update.
Alukal JJ; John S; Thuluvath PJ
Am J Gastroenterol; 2020 Nov; 115(11):1775-1785. PubMed ID: 33156095
[TBL] [Abstract][Full Text] [Related]
25. An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.
Fuller RK; Khambatta PB; Gobezie GC
JAMA; 1977 Mar; 237(10):972-5. PubMed ID: 319263
[TBL] [Abstract][Full Text] [Related]
26. Vasopressin antagonists: role in the management of hyponatremia.
Yeates KE; Morton AR
Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea.
Decaux G; Mols P; Cauchie P; Flamion B; Delwiche F
Nephron; 1986; 44(4):337-43. PubMed ID: 3796773
[TBL] [Abstract][Full Text] [Related]
28. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?
Kitiyakara C; Wilcox CS
Curr Opin Nephrol Hypertens; 1997 Sep; 6(5):461-7. PubMed ID: 9327205
[TBL] [Abstract][Full Text] [Related]
29. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
30. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
Wong F; Gines P; Watson H; Horsmans Y; Angeli P; Gow P; Minini P; Bernardi M
J Hepatol; 2010 Aug; 53(2):283-90. PubMed ID: 20541828
[TBL] [Abstract][Full Text] [Related]
31. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
[TBL] [Abstract][Full Text] [Related]
32. Amiloride ('MK 870') in patients with ascites due to cirrhosis of the liver.
Senewiratne B; Sherlock S
Lancet; 1968 Jan; 1(7534):120-2. PubMed ID: 4169604
[No Abstract] [Full Text] [Related]
33. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
[TBL] [Abstract][Full Text] [Related]
34. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].
Hagège H; Ink O; Ducreux M; Pelletier G; Buffet C; Etienne JP
Gastroenterol Clin Biol; 1992; 16(10):751-5. PubMed ID: 1478401
[TBL] [Abstract][Full Text] [Related]
36. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
[TBL] [Abstract][Full Text] [Related]
37. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.
Arroyo V; Ginès P; Planas R
Gastroenterol Clin North Am; 1992 Mar; 21(1):237-56. PubMed ID: 1568775
[TBL] [Abstract][Full Text] [Related]
38. Refractory ascites: definition and mechanism.
Arroyo V; Badalamenti S; Ginès P
Minerva Med; 1987 May; 78(10):675-80. PubMed ID: 3587714
[No Abstract] [Full Text] [Related]
39. [Hyponatremia in cirrhosis with ascites].
Bronzi G; Orlando D; De Feudis L; Delle Monache G; Scudieri M; Sergiacomo L; Bernardi M; Pesa O
Minerva Med; 1990 Sep; 81(9):591-6. PubMed ID: 2234478
[TBL] [Abstract][Full Text] [Related]
40. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
Fernández-Varo G; Ros J; Cejudo-Martín P; Cano C; Arroyo V; Rivera F; Rodés J; Jiménez W
J Hepatol; 2003 Jun; 38(6):755-61. PubMed ID: 12763368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
